List of Excipients in Branded Drug NAPHCON A

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	NAPHCON A	naphazoline hydrochloride and pheniramine maleate	0065-0085	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	NAPHCON A	naphazoline hydrochloride and pheniramine maleate	0065-0085	BORIC ACID
Alcon Laboratories Inc	NAPHCON A	naphazoline hydrochloride and pheniramine maleate	0065-0085	EDETATE DISODIUM
Alcon Laboratories Inc	NAPHCON A	naphazoline hydrochloride and pheniramine maleate	0065-0085	HYDROCHLORIC ACID
Alcon Laboratories Inc	NAPHCON A	naphazoline hydrochloride and pheniramine maleate	0065-0085	SODIUM BORATE
Alcon Laboratories Inc	NAPHCON A	naphazoline hydrochloride and pheniramine maleate	0065-0085	SODIUM CHLORIDE
Alcon Laboratories Inc	NAPHCON A	naphazoline hydrochloride and pheniramine maleate	0065-0085	SODIUM HYDROXIDE

NAPHCON-A Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

NAPHCON-A is a mature over-the-counter ophthalmic combination containing naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%. Its excipient system is conventional for preserved multidose eye drops: borate buffering, sodium chloride for tonicity, edetate disodium for metal-ion control, benzalkonium chloride as preservative, and purified water as the vehicle. The main commercial opportunity is not a new-molecule patent strategy. It is product differentiation through preservative-free delivery, improved tolerability, packaging, e-commerce positioning, and compliant reformulation.

What is NAPHCON-A and how does its formulation work?

NAPHCON-A is an OTC ophthalmic solution indicated for temporary relief of redness and itching caused by minor eye irritations and allergies. It combines:

Component	Concentration or role
Naphazoline hydrochloride	0.025% active vasoconstrictor
Pheniramine maleate	0.3% active antihistamine
Benzalkonium chloride	0.01% preservative
Boric acid and sodium borate	Buffer system
Sodium chloride	Tonicity adjustment
Edetate disodium	Chelating agent
Purified water	Vehicle

The active combination targets two consumer symptoms. Naphazoline reduces ocular redness through alpha-adrenergic vasoconstriction. Pheniramine reduces histamine-mediated itching. The product is therefore positioned differently from lubricating drops, which address dryness, and from single-agent redness relievers, which do not provide antihistamine activity.

The formulation is a clear, sterile, preserved aqueous solution. The excipients support chemical stability, preservative performance, comfort, and multidose use rather than creating a sophisticated controlled-release system. [1]

What excipients protect the commercial performance of NAPHCON-A?

The highest-value excipient functions are preservative protection, pH control, tonicity control, and container compatibility.

Benzalkonium chloride and preservative strategy

Benzalkonium chloride, commonly abbreviated BAK, allows a multidose bottle to be opened and repeatedly used without microbial contamination under labeled conditions. Its commercial advantages include low cost, established ophthalmic use, and compatibility with conventional low-volume dropper packaging.

Its disadvantages are material. Repeated exposure to BAK can contribute to ocular-surface irritation, tear-film disruption, and reduced acceptability among frequent users. These concerns are most relevant to consumers with dry eye, contact-lens use, chronic allergy, or repeated daily dosing.

BAK is therefore both a cost-efficient excipient and a commercial vulnerability. A competing product can use the absence of BAK as a consumer-facing claim, provided the alternative preservative or container system meets applicable quality and regulatory requirements.

Borate buffer system

Boric acid and sodium borate maintain formulation pH and help preserve product performance during shelf life. Buffer selection affects:

• Active-ingredient stability
• Ocular comfort
• Preservative activity
• Container compatibility
• Manufacturing reproducibility

A reformulator should avoid treating buffer replacement as a simple substitution. Changes in buffer capacity or ionic strength can alter precipitation risk, pH drift, preservative effectiveness, and drop comfort.

Sodium chloride and tonicity

Sodium chloride adjusts osmolarity toward a range that is tolerable for the ocular surface. Excessive deviation from tear-fluid tonicity can create stinging and reduce repeat use. Tonicity must be evaluated together with the active salts, buffer components, and any replacement preservative.

Edetate disodium

Edetate disodium chelates trace metal ions that can catalyze degradation or reduce preservative performance. It can also support preservative efficacy by increasing the susceptibility of microbial cell membranes to the preservative system.

Its concentration is typically low, but its function is important. Removing it without a replacement strategy can affect stability and antimicrobial performance even when the visual appearance of the product remains unchanged.

Purified water and container closure

Purified water is the primary vehicle. The dropper bottle is part of the formulation strategy because the package controls:

• Sterility maintenance after opening
• Drop size
• Dose consistency
• Preservative exposure
• User convenience
• Leakage and evaporation
• Compatibility with BAK and other excipients

A commercial reformulation that changes the bottle, nozzle, or closure may require a broader comparability package than a simple inactive-ingredient change would suggest.

What formulation patents protect NAPHCON-A?

NAPHCON-A is a mature OTC product, and its commercial protection is primarily based on brand equity, regulatory compliance, manufacturing know-how, packaging, and distribution rather than a visible modern patent moat.

The underlying active ingredients, naphazoline and pheniramine, are long-established compounds. A basic combination of these actives in an aqueous ophthalmic solution is unlikely to provide meaningful composition-of-matter exclusivity. Legacy formulation or process patents, if any remain relevant, would need to be assessed by jurisdiction, claim scope, maintenance status, and applicability to the marketed product.

For commercial planning, the relevant IP categories are:

IP category	Likely importance for NAPHCON-A
Active-ingredient patents	Very low; compounds are longstanding
Basic combination patent	Low for a mature OTC combination
Preservative system	Moderate only if tied to a non-obvious performance result
Preservative-free container	Potentially moderate to high
Low-irritation formulation	Potentially moderate, depending on claim scope and data
Drop-size control	Moderate when protected through device or packaging claims
Manufacturing process	Moderate as confidential know-how
Trademark and trade dress	High commercial value
Regulatory exclusivity	Limited for a mature OTC monograph product

The strongest new IP opportunity would involve a technically differentiated platform, such as a preservative-free multidose system, a validated low-irritation formulation, or a container that maintains sterility without BAK. A patent directed only to replacing one buffer or adjusting sodium chloride concentration would face a higher obviousness risk.

What is the FDA regulatory status of NAPHCON-A?

NAPHCON-A is marketed as an OTC ophthalmic drug product. Its regulatory framework is associated with FDA requirements for ophthalmic drug products and applicable OTC monograph conditions, labeling, quality, and manufacturing controls. [2,3]

The principal regulatory requirements include:

• Sterile manufacturing
• Appropriate active-ingredient concentrations
• Microbial limits and preservative control
• Stability through labeled shelf life
• Container-closure integrity
• Accurate Drug Facts labeling
• Warnings for overuse, contact-lens use, and persistent symptoms
• Compliance with current good manufacturing practice

A reformulated product may require an FDA regulatory pathway that depends on the scope of the change. A manufacturer cannot assume that an inactive-ingredient change is commercially or technically minor. The agency may expect updated stability, preservative-effectiveness, container-closure, sterility, extractables and leachables, and human tolerability data.

What is the Orange Book status of NAPHCON-A?

The Orange Book is principally used for approved prescription and certain other FDA-approved drug applications, including patent and exclusivity information. NAPHCON-A is marketed as an OTC ophthalmic product under the nonprescription framework, so Orange Book-listed patent protection is not the central commercial issue.

The absence of an Orange Book patent challenge pathway does not eliminate competitive risk. Competitors can enter through:

• Private-label OTC products
• Store-brand ophthalmic combinations
• Generic-style monograph products
• Authorized or contract-manufactured products
• Reformulated preservative-free products
• Other branded antihistamine-redness relievers

When does NAPHCON-A lose exclusivity?

NAPHCON-A does not have a conventional near-term prescription exclusivity cliff comparable to a patented branded drug. The active ingredients and combination are mature, and the product competes in an OTC market.

Its effective exclusivity consists of four commercial assets:

1. Brand recognition.
2. Retail distribution and shelf placement.
3. Consumer familiarity with the NAPHCON-A name.
4. Manufacturing and packaging execution.

These assets can erode without a formal patent expiration date. Private-label and store-brand competitors can use the same active ingredients if their products comply with FDA requirements. The primary commercial question is therefore not when a patent expires, but whether a competitor can match the product’s efficacy, tolerability, price, packaging, and distribution.

Which companies compete with NAPHCON-A?

NAPHCON-A competes with branded and private-label ophthalmic products that address ocular itching, redness, or both.

Competitor category	Representative products or strategy	Competitive effect
Naphazoline/pheniramine combinations	Opcon-A and store-brand equivalents	Direct active-ingredient competition
Tetrahydrozoline/pheniramine combinations	Visine-A and comparable products	Alternative redness-relief combination
Antihistamine-only drops	Ketotifen products	Stronger allergy-focused positioning
Dual-action prescription-to-OTC allergy drops	Olopatadine products	Higher-value allergy positioning
Lubricating drops	Carboxymethylcellulose, glycerin, polyethylene glycol products	Compete for dry-eye and irritation occasions
Preservative-free products	Unit-dose or multidose preservative-free systems	Target tolerability-sensitive users
Retailer private labels	Store-brand equivalents	Price pressure and shelf substitution

NAPHCON-A is most exposed to direct combination products because they can compete on active ingredients and indications. It is also exposed to newer antihistamine products that can support stronger allergy-focused claims and may be preferred by consumers seeking longer-lasting relief.

What excipient-based commercial opportunities exist?

1. Preservative-free NAPHCON-A equivalent

The clearest opportunity is a preservative-free version using either:

• Unit-dose vials
• A sterilizing multidose container
• A one-way valve system
• An airless or low-contamination bottle
• A proprietary antimicrobial container technology

The commercial tradeoff is cost. Unit-dose packaging increases packaging material, filling complexity, shipping volume, and consumer price. Multidose preservative-free systems reduce some of those costs but require stronger device validation and container-closure performance.

A preservative-free product could target consumers who experience irritation from BAK or who use ophthalmic products frequently. It could also support premium retail pricing if the package communicates a clear tolerability advantage.

2. Low-irritation preserved formulation

A second opportunity is a preserved product that retains multidose convenience while reducing ocular-surface burden. This could involve:

• A lower-irritancy preservative
• Reduced preservative concentration
• A modified buffer system
• Optimized pH and osmolality
• Improved container delivery
• A preservative system with better in-use performance

This strategy requires evidence. A marketing claim that the product is "gentle" is weaker than data showing improved comfort, reduced stinging, or better repeat-use acceptance.

3. Improved drop-size control

A smaller or more consistent drop can reduce active-ingredient waste and improve dosing. Many conventional eye-drop bottles deliver more liquid than the conjunctival sac can retain. A device that delivers a controlled drop could provide:

• Lower product waste
• More predictable exposure
• Greater bottle utilization
• Better consumer satisfaction
• Potential differentiation through device IP

The formulation must remain compatible with the nozzle and should not create excessive force, foaming, or variable delivery during bottle inversion.

4. Contact-lens-compatible positioning

NAPHCON-A labeling restricts use in particular contact-lens circumstances, in part because of preservative and product-use considerations. A new product designed for contact-lens wearers would require a formulation and label strategy that addresses preservative interaction, lens uptake, sterility, and post-application timing.

This is technically attractive but commercially more demanding than a standard reformulation. Contact-lens compatibility would need direct testing rather than reliance on excipient precedent.

5. Improved storage and portability

A smaller bottle, leak-resistant package, tamper-evident closure, or single-use format could expand travel and on-the-go use. These changes are more likely to generate trade-dress, device, or packaging differentiation than pharmaceutical patent protection.

6. Pediatric and household safety packaging

The active ingredients create a need for clear warnings and child-resistant packaging strategies. Improved dispensing control and packaging communication may reduce accidental misuse. These changes can support retailer acceptance and risk-management objectives even when they do not create exclusivity.

How strong is the NAPHCON-A patent estate?

The patent estate is likely weak as a barrier to direct active-ingredient substitution and moderate only for newly developed formulation or device improvements.

Factor	Assessment
Active ingredients	Weak barrier because of long market history
Combination concept	Weak-to-moderate, depending on jurisdiction and claim history
Conventional excipients	Weak; most are established ophthalmic materials
BAK-preserved solution	Weak unless tied to unusual stability or tolerability data
Preservative-free delivery	Potentially stronger
Device and bottle design	Potentially stronger than formulation claims
Manufacturing process	Moderate through trade secrets and process control
Brand and trade dress	Commercially important
FDA regulatory barrier	Manageable for compliant OTC competitors

A patent strategy should focus on measurable technical outcomes. Examples include sterility maintenance after repeated opening, reduced preservative exposure, improved active stability, controlled drop volume, reduced ocular stinging, or improved compatibility with contact lenses.

What generic entry risks exist for NAPHCON-A?

Generic-style entry risk is high because the product is mature, the active ingredients are available, and the formulation does not depend on a complex delivery platform.

The most likely entry scenarios are:

Low-cost direct equivalent

A manufacturer can offer the same active ingredients and a similar preserved aqueous formulation at a lower price. This is the fastest route to share erosion.

Retail private label

Retailers can place a naphazoline/pheniramine equivalent beside NAPHCON-A and compete on price. The brand may retain consumers who recognize the name, but casual purchasers are price-sensitive.

Premium preservative-free alternative

A competitor can avoid direct price competition by targeting users concerned about BAK, stinging, or frequent application. This product could take share from NAPHCON-A even at a higher price.

Newer allergy product

Ketotifen or olopatadine products can compete by emphasizing allergy treatment rather than general redness relief. This creates therapeutic substitution rather than direct generic substitution.

What patent litigation and Paragraph IV challenges affect NAPHCON-A?

NAPHCON-A is not positioned like a prescription product with a standard Orange Book patent challenge cycle. Paragraph IV litigation is therefore not the expected principal entry mechanism for competing OTC monograph products.

The more relevant legal risks are:

• Trademark infringement
• Trade-dress disputes
• False or unsupported superiority claims
• Labeling disputes
• Regulatory compliance actions
• Device or packaging patent litigation
• Contract-manufacturing and formulation confidentiality disputes

A competitor developing a preservative-free bottle or controlled-drop device may face patent risk from packaging and ophthalmic-delivery companies, even when the active formulation itself is unprotected.

How does NAPHCON-A compare with newer allergy eye drops?

Attribute	NAPHCON-A	Ketotifen products	Olopatadine products
Active profile	Vasoconstrictor plus antihistamine	Antihistamine with mast-cell activity	Antihistamine with mast-cell activity
Primary consumer message	Relief of itching and redness	Allergy itching relief	Allergy itching relief
Redness benefit	Direct vasoconstrictor effect	Less central	Less central
Preservative-free opportunity	High	High	High
OTC positioning	Established	Established	Established
Generic substitution risk	High	High	High
Formulation differentiation	Moderate	Moderate-to-high	Moderate-to-high
Long-term ocular-surface concern	Relevant because of BAK and vasoconstrictor use	Depends on product	Depends on product

NAPHCON-A retains a clear use case for consumers seeking simultaneous relief of redness and itching. Newer allergy products may have stronger positioning for recurrent allergic conjunctivitis and may avoid the drawbacks associated with vasoconstrictor use.

What is the revenue exposure and commercial outlook?

Public revenue reporting is unlikely to isolate NAPHCON-A sales from broader ophthalmic OTC portfolios. The commercial exposure should be assessed through channel-level indicators:

• Retail velocity
• Weighted distribution
• Average selling price
• Private-label price gap
• Repeat purchase rate
• Share of preservative-free sales
• E-commerce search volume
• Promotion frequency
• Gross margin after packaging costs

The brand’s revenue risk is highest where retailers prioritize private-label substitution and where consumers purchase based on active ingredient rather than brand. The highest-value growth opportunity is a premium reformulation that expands the user base without surrendering the original multidose product.

A two-tier portfolio is commercially rational:

1. Maintain the existing preserved multidose product as the value and convenience option.
2. Launch a preservative-free or low-irritation product at a premium.

The strategy should preserve the NAPHCON-A name while creating a differentiated sub-brand or package architecture. A direct reformulation that raises cost without communicating a clear benefit would have weaker economics.

Key Takeaways

• NAPHCON-A contains naphazoline hydrochloride 0.025% and pheniramine maleate 0.3%.
• Its excipient system uses BAK, borate buffering, sodium chloride, edetate disodium, and purified water.
• BAK supports low-cost multidose packaging but creates a tolerability-based differentiation opportunity.
• The product has limited apparent protection from active-ingredient or conventional formulation patents.
• Orange Book and Paragraph IV mechanisms are less central than OTC compliance, trademark, trade dress, and device IP.
• The strongest commercial opportunity is a preservative-free or low-irritation product supported by improved packaging.
• Direct generic and private-label substitution risk is high.
• A two-tier strategy combining the established product with a premium preservative-free format offers the clearest path to share defense and incremental revenue.

FAQs

Can NAPHCON-A be reformulated without benzalkonium chloride?

Yes, but the replacement requires a validated preservative or a preservative-free container system. The manufacturer must establish sterility maintenance, preservative effectiveness where applicable, stability, container compatibility, and acceptable ocular tolerability.

Is a preservative-free NAPHCON-A likely to receive premium pricing?

Yes. Preservative-free ophthalmic products can support premium pricing when they target frequent users, dry-eye patients, contact-lens users, or consumers who experience irritation from preserved drops. Packaging cost and consumer education will determine margin quality.

Are naphazoline and pheniramine suitable for a new ophthalmic combination patent?

A basic combination patent would face substantial patentability risk because both actives and their ophthalmic use are longstanding. A stronger application would require a defined technical improvement, such as controlled drop delivery, improved stability, reduced irritation, or a validated preservative-free system.

What is the main manufacturing barrier for a competing NAPHCON-A product?

The principal barrier is sterile ophthalmic manufacturing with consistent drop delivery and reliable container-closure performance. The active ingredients and conventional excipients are comparatively accessible.

Which product has greater long-term commercial potential: NAPHCON-A or a newer antihistamine drop?

NAPHCON-A has durable brand and redness-relief positioning but high substitution risk. Newer antihistamine products may have stronger recurring allergy-treatment positioning. The higher-potential platform depends on whether the strategy prioritizes broad OTC recognition, premium preservative-free delivery, or chronic allergy use.

References

1. DailyMed. (n.d.). NAPHCON-A naphazoline hydrochloride and pheniramine maleate ophthalmic solution: Drug label. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). OTC monograph for ophthalmic drug products. https://www.fda.gov/

3. Code of Federal Regulations. (2024). 21 C.F.R. Part 349: Ophthalmic drug products for over-the-counter human use. U.S. Government Publishing Office. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-349

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. U.S. Food and Drug Administration. (2023). Container closure systems for packaging human drugs and biologics: Guidance for industry. U.S. Department of Health and Human Services. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/guidance-documents-inspections-and-compliance】【。